NeuroVive—SEK 35 m private placement complete, more information on forthcoming SEK 75.8 m rights issue

The private placement reported to the market on 20 November 2013 and approved by
the Extraordinary General Meeting (EGM) on 13 December 2013 is now complete.
A total of 2,500,000 shares were subscribed at SEK 14 per share, which raises
NeuroVive SEK 35 m before issue expenses. Due to the share issue, share capital
has increased by SEK 125,000.

Waiving shareholders’ preferential rights, the shares in the private placement
were subscribed by reputable Swedish institutional investors including
pharmaceutical fund Rhenman & Partners, National Swedish pension fund AP2, other
institutional investors, and Dr. Guo Weicheng, co-founder of Sihuan
Pharmaceutical (NeuroVive’s collaboration partner in China).

IR portal launched for forthcoming rights issue
NeuroVive is also reporting that the company has launched an IR portal for the
company’s forthcoming rights issue, with subscription period 13 January 2014 to
27 January 2014 inclusive. The portal, which is at www.irportalen.se/neurovive,
will provide critical information, videos with key employees of the company and
a facility for ordering prospectuses and booking a place at one of the following
planned investor events:

  · Gothenburg: Folkets Hus, 15 January 6:00 p.m., Olof Plames Plats 3
  · Lund: Grand Hotell, 16 January, 6:00 p.m., Bantorget 1
  · Stockholm: 7A Odenplan, 20 January, 6:00 p.m., Norrtullsgatan 6
  · Conference call: 21 January, 5:00 p.m.

The forthcoming rights issue will provide existing shareholders with one
subscription right per share, and four subscription rights confer entitlement to
subscribe for one new share at the price of SEK 14 per share. The share issue
will involve a maximum of 5,414,761 shares, which would raise the company some
SEK 75.8 m before issue expenses. The record date for determining which
shareholders are entitled to participate in this share issue cum rights is 8
January 2014. It is also possible to apply for allotment of shares without
preferential rights.

About NeuroVive
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of anti-viral indications
(Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

Media and investor relations questions to:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 6221 or ir@neurovive.com
Please also use the above contact if you wish to arrange an interview with
NeuroVive’s CEO, Mikael Brönnegård.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 6220 (switchboard), Fax: +46 (0)46 888 8348
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this news release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication at 13:15 CEST on
18 December 2013.